Journal of Clinical and Cellular Immunology
Open Access
ISSN: 2155-9899
+44 1223 790975
ISSN: 2155-9899
+44 1223 790975
Zarghi A, Zali A, Ashrafi F and Moazzezi S
Accepted Abstracts: J Clin Cell Immunol
HCV infection is associated to several autoimmune comorbidities such as cryoglobulinaemia, porphyria cutanea tarda, lichen planus, cutaneous polyarteris nodosa and for a variety of other dermatological conditions including psoriasis, urticaria, and erythema multiforme (EM). Chronic hepatitis C and peg-interferon alpha/ribavirin treatment dermotological side effects are well known. New direct-acting antivirals have led to significant improvements in sustained virologic response rates, but several have led to an increase in dermatological side affects versus peginterferon (peg-İFN)/ribavirin (RBV) alone. A 55-year old man was administered peg-İFN alpha-2a (180 mcg, once a week )/RBV (1200 mg daily) and telaprevir (2250 mg daily) with the diagnosis of chronic hepatitis C. At the 8th week of the treatment erythematous rash developed. On the 12th administration of the combination therapy, the patient admitted to our hospital with, fever, elevated neutrophils, facial edema with excoriations and rash initially involved, rapidly spread to the body. The patient had been diagnosed as acute generalized exanthematous pustulosis and he was hospitalised. AGEP is generally characterized by an acute, widespread edematous erythema with the presence of small non-follicular pustulosis mostly in the folds and the face, and is associated with elevated neutrophils and high fever. As a result, with the advent of the new direct-acting antivirals, dermatological manifestations will be seen more frequently so patients should be monitored closely in terms of dermatological side effects.